Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2018

View Archived Issues

Nilotinib regimen feasible in chronic myeloid leukemia blastic phase, acute myeloid leukemia

RAC2 found as novel target in mantle cell lymphoma

FadD32 inhibitors with quinoline scaffold are more stable and have antitubercular activity in mouse

The ABCs of RAF

Scientists gain new insights into function of NLRC3

Novel more soluble ferrostatin-1 analogues inhibiting ferroptosis in vivo

Recruitment ongoing in phase I study of IBI-188

Shenyang Research Institute of Chemical Industry patent reports IDO1 inhibitors

University of Pisa researchers describe GLP-1 receptor agonists

Glucose-lowering agents revealed in Daiichi Sankyo patent

Compounds for treatment of seizure disorders described in Otsuka patent

ChemoCentryx divulges C5aR antagonists

First patient dosed in pivotal phase III PROTECT study of sparsentan

Incyte Corporation initiates phase III FIGHT-302 trial of pemigatinib

Small studies, in the aggregate, yield "robust data" on thrombosis

Sustained clinical benefit in patients with beta-thalassemia following LentiGlobin gene therapy

Novel CD19+CD22 CAR-T cocktail shows safety and efficacy in phase I study

Ibrutinib plus rituximab is superior to conventional chemotherapy for chronic lymphocytic leukemia

Addition of daratumumab to lenalidomide and dexamethasone improves outcome of multiple myeloma

Kyorin Pharmaceutical and Yissum enter respiratory drug development collaboration

JHL initiates phase III trial of rituximab biosimiilar JHL-1101

Bridge Biotherapeutics initiates phase II study of BBT-401

University of Pennsylvania pilot study explores mature dendritic cell vaccine for pancreatic cancer

FDA approves sNDA to expand the age range for Ravicti oral liquid to include newborns

Perlara and Rambam Medical Center enter APOL1 kidney disease partnership

SRS-143 demonstrates promising results in preclinical models of asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...